NCT02548559View on ClinicalTrials.gov

Sublingual Cannabidiol for Anxiety

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 14, 2018

Primary Completion Date

March 13, 2025

Study Completion Date

March 13, 2025

Conditions
Anxiety
Interventions
DRUG

Full-Spectrum Cannabidiol

Full-Spectrum Cannabidiol; total daily dose of 30 mg.

DRUG

Single-Compound Cannabidiol

Single-Compound Cannabidiol; total daily dose of 30 mg.

DRUG

Placebo

Placebo solution.

Trial Locations (1)

02478-9106

McLean Hospital Brain Imaging Center, Belmont

All Listed Sponsors
lead

Staci Gruber, Ph.D.

OTHER

NCT02548559 - Sublingual Cannabidiol for Anxiety | Biotech Hunter | Biotech Hunter